To require coverage of annual glaucoma screenings for certain individuals, and for other purposes.

HR10476, the 'Glaucoma Screening Coverage Act,' was introduced in the House on September 16, 2026, and referred to the Committees on Energy and Commerce, Ways and Means, and Oversight and Government Reform. The bill mandates coverage of annual glaucoma screenings for certain high-risk individuals (e.g., those with diabetes, family history, or age over 60) under private health plans and federal programs like Medicare and Medicaid. It does not appropriate funds; it imposes a coverage mandate on insurers and government programs, which would increase utilization of eye-care services. The bill is at the earliest legislative stage—committee referral—with no hearings, markup, or floor votes scheduled. Given the 119th Congress is in its second session, the likelihood of enactment is low absent strong bipartisan support. The primary economic effect would be on health insurers (e.g., UnitedHealth, Anthem) facing slightly higher claims costs, and on eye-care providers and diagnostic equipment makers (e.g., Topcon, Zeiss, Nidek) seeing increased demand for screenings. However, the causal chain is indirect: the bill does not name any company, and the revenue impact on any single provider is diffuse. No real market data was provided, so no price movements are cited. The bill's impact score is 2/10—procedural with no near-term market effect. The convergence analysis found no direct or industry-level candidates in the provided set; all candidates were dropped for lacking a specific shared technology class or objective. The bill remains a standalone healthcare coverage measure with minimal investment relevance at this stage.